Xeljanz woes are likely to be boost to Rinvoq, which is already growing fast – making $450 million in the first nine months of 2020, including $215 million in the third quarter alone.

Xeljanz is not approved in rheumatoid arthritis in Europe at the higher dose, but is available in that dose in the US, and Pfizer’s data came from a cardiovascular post-marketing safety study ...